Targets › LAIR2
1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Dec 2028.
Open in Phaseline: the race on LAIR2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NC410 LAIR-2 fusion protein | LAIR2 | Phase 2 | Pancreatic Cancer | Dec 2028 |
Pancreatic Cancer (1)
mixed (1)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.